Ponatinib in Philadelphia chromosome-positive leukemias

New England Journal of Medicine

Volumn 370, Issue 6, 2014, Pages 577-

  Quintas Cardama, Alfonso ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PONATINIB; IMIDAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDAZINE DERIVATIVE;

ARTERY THROMBOSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; GENE MUTATION; HUMAN; LETTER; LEUKEMIA; LIVER TOXICITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHILADELPHIA 1 CHROMOSOME; PHILADELPHIA CHROMOSOME POSITIVE LEUKEMIA; PRIORITY JOURNAL; ACUTE LYMPHOBLASTIC LEUKEMIA; CHEMICALLY INDUCED DISORDER; CHRONIC MYELOID LEUKEMIA; FEMALE; MALE; NOTE; THROMBOSIS;

FEMALE; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PYRIDAZINES; THROMBOSIS;

EID: 84893578349     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1315234     Document Type: Letter

References (2)

1. Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013;369:1783-96.
2. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012;367:2075-88.